Goldman Sachs Maintains Neutral on Incyte, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter has maintained a Neutral rating on Incyte (NASDAQ:INCY) but has lowered the price target from $98 to $65.
November 22, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Incyte but reduced the price target from $98 to $65, indicating a potential downside based on their analysis.
The reduction in price target by a significant margin from $98 to $65 by Goldman Sachs suggests that the bank's analysts see less upside potential in Incyte's stock, which could lead to a negative investor sentiment and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100